Code of Maine Rules
10 - DEPARTMENT OF HEALTH AND HUMAN SERVICES
144 - DEPARTMENT OF HEALTH AND HUMAN SERVICES - GENERAL
Chapter 258 - RULES FOR THE CONTROL OF NOTIFIABLE DISEASES AND CONDITIONS
Appendix A - NOTIFIABLE DISEASES AND CONDITIONS LIST

Universal Citation: 10 ME Code Rules ยง A
Current through 2024-38, September 18, 2024

* Category I Diseases must be reported to the Department immediately.

** Category II Diseases must be reported within 48 hours of the diagnosis or laboratory test result.

# Laboratories are to submit isolates or clinical specimens for the following, as well as any isolates or clinical specimens, as requested by HETL for confirmation, typing and/or antibiotic sensitivity.

Table 1.

Notifiable Diseases and Conditions

Disease or Condition

Agent

**

Acquired immunodeficiency syndrome (AIDS)

Human immunodeficiency virus

**

Acute flaccid myelitis (AFM)1

**

Anaplasmosis

Anaplasmaphagocytophilum

*

#

Anthrax

Bacillus anthracis

**

Babesiosis

Babesia microti

*

#

Botulism

Clostridium botulinum

**

Borrelia miyamotoi

Borrelia miyamotoi

*

#

Brucellosis

Brucella species

**

California serogroup viruses

**

Campylobacteriosis

Campylobacter species

*

#

Candida auris2

Candida auris

*

#

Carbapenemase-producing carbapenem-resistant organisms3

Enterobacteriaceae spp.

Pseudomonas aeruginosa (non-mucoid only)

Acinetobacter baumannii

**

Carbon monoxide poisoning4

Carbon monoxide

**

Chancroid

Haemophilusducreyi

**

Chlamydia

Chlamydia trachomatis

**

Chickenpox (varicella)

Varicella-zoster virus

**

Chikungunya

Chikungunya virus

*

#

Coronavirus (novel, MERS, and SARS)

Coronavirus

**

Creutzfeldt-Jakob disease, < 55 years of age

Creutzfeldt-Jakob agent

**

Cryptosporidiosis

Cryptosporidium species

**

Cyclosporiasis

Cyclospora

**

Dengue

Dengue fever virus

Disease or Condition

Agent

*

#

Diphtheria

Corynebacterium diphtheriae

**

#

E.coli, Shiga toxin-producing (STEC)

Escherichia coli, Shiga toxin-producing

**

Eastern equine encephalitis

Eastern equine encephalitis virus

**

Ehrlichiosis

Ehrlichiaspecies

**

Giardiasis

Giardia species

**

Gonorrhea

Neisseria gonorrhoeae

**

#

Haemophilus influenzae,invasive

Haemophilus influenzae

**

Hantavirus, pulmonary and non-pulmonary syndromes

Hantavirus

**

Hemolytic-uremic syndrome (post-diarrheal)

Escherichia coli, Shiga toxin-producing

*

Hepatitis A, B, C, D, E (acute)

Hepatitis A, B, C, D, E viruses

**

Hepatitis B, C, D (chronic)

Hepatitis B, C, D viruses

**

Human immunodeficiency virus (HIV)5

Human immunodeficiency virus

**

Influenza-associated pediatric death

Influenza virus

*

#

Influenza A, novel

Influenza virus

**

Influenza-associated hospitalizations, laboratory-confirmed

Influenza virus

**

Legionellosis

Legionella species

**

Leptospirosis

Leptospira species

**

#

Listeriosis

Listeria monocytogenes

**

Lyme disease

Borrelia burgdorferi

**

Malaria

Plasmodium species

*

#

Measles

Rubeola virus

*

#

Meningococcal disease, invasive

Neisseria meningitidis

*

#

Mumps

Mumps virus

*

Pertussis

Bordetella pertussis

*

#

Plague

Yersinia pestis

*

#

Poliomyelitis

Poliovirus

**

Powassan

Powassan or deer tick virus

**

Psittacosis

Chlamydia psittaci

*

Q fever

Coxiella burnetii

*

#

Rabies (human and animal)

Rabies virus

**

Rabies post-exposure prophylaxis

*

#

Ricin poisoning

*

#

Rubella (including congenital)

Rubella virus

**

#

Salmonellosis

Salmonella species

*

Shellfish poisoning

**

#

Shigellosis

Shigella species

*

#

Smallpox

Variola virus

**

Spotted fever rickettsiosis

Rickettsia rickettsii

Disease or Condition

Agent

**

St. Louis encephalitis

St. Louis encephalitis virus

*

#

Staphylococcus aureus non-susceptible to vancomycin6

Staphylococcus aureus

**

Streptococcus group A, invasive

Streptococcus pyogenes (group A beta hemolytic strep)

**

Streptococcus pneumoniae, invasive

Streptococcus pneumoniae

**

Syphilis

Treponema pallidum

*

#

Tetanus

Clostridium tetani

**

Trichinosis

Trichinella species

*

#

Tuberculosis (active and presumptive)

Mycobacterium tuberculosis

*

#

Tularemia

Francisellatularensis

**

#

Vibrio species, including cholera

Vibrio species

**

Vaping-associated pulmonary illness7

*

Viral hemorrhagic fever

Arenaviruses and others

**

West nile

West nile virus

**

Western equine encephalitis

Western equine encephalitis virus

**

Yellow fever

Yellow fever virus

**

Zika virus disease

Zika virus

*

Any case of unusual illness of infectious cause

*

Any cluster/outbreak of illness with potential public health significance

1 An illness with an onset of acute focal limb weakness and either 1) cerebrospinal fluid with an elevated white blood cell count or 2) a magnetic resonance image (MRI) showing a spinal cord lesion largely restricted to gray matter and spanning one or more spinal segments.

2 Detection of Candida auris in a specimen using culture or culture independent diagnostic test; or detection of an organism that commonly represents a Candida auris misidentification.

3 Carbapenemase-producing carbapenem-resistant organisms are:

* Carbapenem-resistant organisms, as defined by the Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com), that test positive for Carbapenemase-producing by a phenotype method or for a known carbapenemase resistance mechanisms by a recognized test, as defined by the U.S. Centers for Disease Control and Prevention (https://wwwn.cdc.gov/nndss/conditions/carbapenemase-producing-carbapenem-resistant-enterobacteriaceae/case-definition/2018/).

* Reporting will include test method used, result, and where applicable, specific resistance mechanisms identified.

* Isolate submission is required for all carbapenem-producing carbapenem-resistant organisms. If phenotypic or resistance mechanism test results are not available for a carbapenem-resistant organism, then isolate submission of the carbapenem-resistant organism is required to determine carbapenemase-producing status.

4 All cases with clinical signs, symptoms or known exposure consistent with diagnosis of carbon monoxide poisoning, and/or: a carboxyhemoglobin (COHb) level equal to or above 5%.

5Any human immunodeficiency virus (HIV) test results, including:

* All reactive/repeatedly reactive initial HIV immunoassay results and all results (e.g. positive, negative, indeterminate) from all supplemental HIV immunoassays (HIV-1/2 antibody differentiation assay, HIV-1 Western blot, HIV-2 Western blot or HIV-1 Immunofluorescent assay);

* All HIV nucleic acid (RNA or DNA) detection tests (qualitative and quantitative), including tests on individual specimens for confirmation of nucleic acid amplification testing (NAAT) screening results;

* All CD4 lymphocyte counts and percentages, unless known to be ordered for a condition other than HIV;

* HIV genotypic resistance testing, nucleotide sequence results; and,

* Positive HIV detection tests (including, but not limited to culture, P24 antigen).

6 As defined by the most current Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com).

7 Clinicians should report cases with onset on or after May 1, 2019, that meet the criteria of (1) a significant respiratory illness of unclear etiology and (2) a history of vaping.

Disclaimer: These regulations may not be the most recent version. Maine may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.